JPH11511018A - 遺伝子治療のための自己削除性ベクター - Google Patents

遺伝子治療のための自己削除性ベクター

Info

Publication number
JPH11511018A
JPH11511018A JP9508854A JP50885497A JPH11511018A JP H11511018 A JPH11511018 A JP H11511018A JP 9508854 A JP9508854 A JP 9508854A JP 50885497 A JP50885497 A JP 50885497A JP H11511018 A JPH11511018 A JP H11511018A
Authority
JP
Japan
Prior art keywords
vector
recombinase
genome
sequences
target sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9508854A
Other languages
English (en)
Japanese (ja)
Inventor
メルフネル，ハラルド フオン
ルス，アンドレアス，ペテル
グレツ，マヌエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH11511018A publication Critical patent/JPH11511018A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP9508854A 1995-08-18 1996-02-23 遺伝子治療のための自己削除性ベクター Pending JPH11511018A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19530412.8 1995-08-18
DE1995130412 DE19530412A1 (de) 1995-08-18 1995-08-18 Selbst deletierende retrovirale Vektoren für die Gentherapie
PCT/EP1996/000761 WO1997007223A1 (fr) 1995-08-18 1996-02-23 Vecteurs a auto-suppression pour therapie genique

Publications (1)

Publication Number Publication Date
JPH11511018A true JPH11511018A (ja) 1999-09-28

Family

ID=7769797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9508854A Pending JPH11511018A (ja) 1995-08-18 1996-02-23 遺伝子治療のための自己削除性ベクター

Country Status (5)

Country Link
EP (1) EP0845041A1 (fr)
JP (1) JPH11511018A (fr)
AU (1) AU4941096A (fr)
DE (1) DE19530412A1 (fr)
WO (1) WO1997007223A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN903196A0 (en) * 1996-03-29 1996-04-26 Australian National University, The Single-step excision means
GB9810423D0 (en) * 1998-05-15 1998-07-15 Cancer Res Campaign Tech Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
DE19834430C2 (de) 1998-07-30 2000-05-31 Harald Von Melchner Selbstdeletierende Vektoren für die Krebstherapie
EP1103614B1 (fr) * 1999-06-04 2010-06-02 Nippon Institute for Biological Science Nouveau vecteur plasmidique
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
WO2001079471A2 (fr) * 2000-04-12 2001-10-25 Dana-Farber Cancer Institute Recombinases auto-extinguibles, acides nucleiques qui les codent et procedes pour leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300422B1 (fr) * 1987-07-21 1992-12-02 The Du Pont Merck Pharmaceutical Company Méthode de préparation de vecteurs viraux recombinants stables et viables pour les cellules animales
US5527695A (en) * 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター

Also Published As

Publication number Publication date
AU4941096A (en) 1997-03-12
EP0845041A1 (fr) 1998-06-03
DE19530412A1 (de) 1997-02-20
WO1997007223A1 (fr) 1997-02-27

Similar Documents

Publication Publication Date Title
Wolff et al. Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years
Miller Retroviral vectors
JP4482578B2 (ja) 真核細胞にヌクレオチド配列を挿入し得る天然または合成のレトロエレメント配列
US5714353A (en) Safe vectors for gene therapy
Anson The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery
US20170145438A1 (en) Viral Vectors for Gene Editing
JPH10500287A (ja) 非交差性レトロウイルスベクター
JP2008301826A (ja) ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
EP0688358A1 (fr) Vecteurs ameliores en therapie genique
JP2017505626A (ja) 鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン
JPH09511405A (ja) レトロウイルスベクターハイブリッド及びその遺伝子転移のための使用
US7056730B2 (en) Expression of heterologous genes from an IRES translational cassette in retroviral vectors
JP2000514284A (ja) Ｓａｒエレメントを有するベクター
JPH10507628A (ja) 非自己不活化性の発現標的化レトロウイルスベクタ
JPH11511018A (ja) 遺伝子治療のための自己削除性ベクター
JPH11511651A (ja) 遺伝子治療に特に適した改良型レトロウイルスベクター
JPH09501046A (ja) β−グロビン遺伝子およびβ−遺伝子座制御領域誘導体を導入するためのレトロウイルスベクター
JP4708661B2 (ja) 増強された３’転写終結構造を含む、レトロウイルスベクター
JP2000504585A (ja) １０ａ１レトロウィルスパッケージング細胞及びその使用
EP0511311A1 (fr) Nouveaux vecteurs retroviraux
CA2228159A1 (fr) Vecteurs a auto-suppression pour therapie genique
IL116216A (en) Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
JP3877769B2 (ja) 組み換えレトロウイルス産生細胞
CA2199131C (fr) Hybrides vectoriels retroviraux et leur utilisation pour le transfert de genes
Hodgson et al. Retroviral vectors for gene therapy and transgenics